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In this paper we present information about a material selectively removing prothrombin from an eluate containing prothrombin, proconvertin, and hemophilia B factor (PTC, Christmas factor). The substance exhibiting this unique behavior is asolectin.
In another communication (1) we have reported that suitable concentrations of asolectin used with the described technique selectively adsorb proaccelerin from citrated human plasma. Greater concentrations of asolectin, however, led to the loss of prothrombin and still greater concentrations to marked loss of fibrinogen reactivity. In both the latter instances, surprisingly, proconvertin activity was little reduced.
Accordingly, using the dialyzed eluate of washed barium sulfate that had adsorbed prothrombin, proconvertin, and hemophilia B factor from fresh oxalated normal human plasma, it was possible to demonstrate that selective, almost complete, removal of prothrombin activity by asolectin can be effected with only minor depletion of proconvertin activity. The ability of the asolectin treated eluate to shorten the partial thromboplastin time of hemophilia B plasma was moderately reduced.
MATERIALS
Oxalated normal platelet poor plasma was prepared as previously described (1) . The Prothrombin free ox plasma.
Citrated, proconvertin-deficient plasma was prepared from the blood of a patient congenitally deficient in this factor as previously described (3). Citrated, hemophilia B plasma was similarly prepared from the blood of a patient with the classical laboratory and clinical findings of hemophilia B (PTC deficiency, Christmas disease). The supernatant plasma was transferred with a Pasteur pipette to a glass bottle, and glassactivated (4). It was then decanted and bottled in aliquots which were stored at minus 20°C. and thawed immediately before use. Saline extract human brain thromboplastin was prepared as previously described (5) .
Aged citrated human serum was prepared as described by Owren and Aas (6) and by Aas (7) .
Calcium chloride aqueous solutions were prepared in the molarities indicated in the individual test systems.
Diluting fluid I and II were prepared as previously described (1).
Veronal buffer (pH 7.35, ionic strength 0.154) was prepared as described previously (2) .
Buffer saline was prepared as previously described (1). Adsorbed ox plasma was prepared as previously described (6) by passing fresh oxalated ox plasma once through a 20 per cent asbestos, then twice through a 50 per cent asbestos filter.
Accelerin-calcium chloride 30 mM was prepared by adding 0.5 ml. of thrombin (Hemoclaudan Adrenon Leo, Lovens Kemiske Fabrik, Kobenhavn, 100 units per ml. dissolved in veronal buffer) to 10 ml. of adsorbed ox plasma at 37°C. After 30 minutes' incubation, the fibrin was removed from the clotted plasma. Thrombin addition, incubation, and defibrination were repeated two more times. The resulting accelerin was then diluted with an equal volume of 60 mM calcium chloride solution to produce accelerin-calcium chloride 30 mM. Aliquots were stored at minus 20°C. and retained sufficient potency for use for periods of one week or more. During tests the accelerin-calcium chloride 30 mM was kept at 370C. (2) and of Owren and Aas (6) were both used.
The proconvertin assay system using plasma from a patient congenitally deficient in proconvertin as substrate was as previously described (1, Attempts to elute prothrombin from the asolectin with 0.14 M sodium citrate, with 0.9 per cent sodium chloride, with distilled water, with 1 per cent acetic acid, and with phosphate buffer (pH 8.0) have not succeeded. Attempted solution of asolectin and precipitation of prothrombin by adding a 10 per cent volume of ethyl ether (4°C.), attempts to achieve differential solubility of prothrombin and asolectin in tri-fluoro acetic acid, and attempts to oxalate and competitively adsorb prothrombin on barium sulfate from the asolectin and elute it from the barium sulfate have all been unsuccessful. Efforts to separate the prothrombin are continuing. The probability that the bond between asolectin and prothrombin may be chemical rather than physical is recognized. SUMMARY Asolectin 30 mg. per ml. ground to an even suspension in a mortar and pestle with a dialyzed sodium citrate eluate of the barium sulfate adsorbent of fresh oxalated normal human plasma is capable of selectively and almost completely removing prothrombin activity. Proconvertin activity and the ability of the treated eluate to shorten the partial thromboplastin time of hemophilia B plasma are reduced to a much lesser degree. The asolectin suspension is incubated with the eluate for 60 minutes at 4°C., then sedimented by centrifugation at 40,000 rpm for 60 minutes (20C.).
Attempts to elute the prothrombin from asolectin have been unsuccessful to date.
